Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Adv Mater. 2017 Nov 22;30(4):10.1002/adma.201700859. doi: 10.1002/adma.201700859

Figure 10.

Figure 10

Selected results from hemostatic studies with infusible platelet membrane (IPM) technology, where (10 A) addition of IPM in thrombocytopenic blood perfused ex vivo in rabbit aorta segments dose-dependently increased fibrin deposition at low and high shear rates and (10B) in vivo administration of IPM in thrombocytopenic rabbits resulted in significant reduction of bleeding time. Figure components adapted and reproduced with permission.[401,402] Copyright 2000, John Wiley & Sons Inc. and 2012, IJPSR.